Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis

G. Pignataro, A. Vinciguerra, O. Cuomo, R. Sirabella, G. F. Di Renzo, A. Scorziello

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ligneous conjunctivitis is a severe and rare chronic "idiopathic membraneous" conjunctivitis, characterized by the formation of pseudomembranes mostly on the palpebral surfaces that progressively replace the normal mucosa. Evidence has been provided that ligneous conjunctivitis is caused by a severe systemic plasminogen deficiency with decreased plasminogen antigen and decreased plasminogen functional activities. Objective of the present study is to verify the hypothesis that a topical eye application of plasminogen is able to ameliorate the consequences of this disease. Here we report the results of pre-clinical studies performed to investigate the therapeutic effectiveness of an eye-drop plasminogen preparation in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. The entity of protection mediated by plasminogen was evaluated by measuring the extent of the eye lesion by means of a computerized system and dedicated software. The results of the present study clearly showed that the administration for six times a day of plasminogen eye-drop solution in the lesioned eye of animals knock-out for plasminogen gene and developing ligneous conjunctivitis caused a dose and time related reduction of the extent of the ocular lesion. These findings may pave the road for the pharmacological treatment of the ocular lesion associated to the ligneous conjunctivitis that at the present is surgically treated by removing the pseudomembranes generated on the eye.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalPharmacological Research
Volume74
DOIs
Publication statusPublished - 2013

Fingerprint

Plasminogen
Transgenic Mice
Ophthalmic Solutions
Gene Knockout Techniques
Conjunctivitis
Type I Plasminogen Deficiency
Eyelids
Mucous Membrane
Software
Pharmacology
Antigens

Keywords

  • B6.129P2-Plg transgenic mice
  • Eye lesion
  • Ligneous conjunctivitis
  • Plasminogen

ASJC Scopus subject areas

  • Pharmacology

Cite this

Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. / Pignataro, G.; Vinciguerra, A.; Cuomo, O.; Sirabella, R.; Di Renzo, G. F.; Scorziello, A.

In: Pharmacological Research, Vol. 74, 2013, p. 45-48.

Research output: Contribution to journalArticle

Pignataro, G. ; Vinciguerra, A. ; Cuomo, O. ; Sirabella, R. ; Di Renzo, G. F. ; Scorziello, A. / Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. In: Pharmacological Research. 2013 ; Vol. 74. pp. 45-48.
@article{c70985eb06bd4ead870b329e17c2c47d,
title = "Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis",
abstract = "Ligneous conjunctivitis is a severe and rare chronic {"}idiopathic membraneous{"} conjunctivitis, characterized by the formation of pseudomembranes mostly on the palpebral surfaces that progressively replace the normal mucosa. Evidence has been provided that ligneous conjunctivitis is caused by a severe systemic plasminogen deficiency with decreased plasminogen antigen and decreased plasminogen functional activities. Objective of the present study is to verify the hypothesis that a topical eye application of plasminogen is able to ameliorate the consequences of this disease. Here we report the results of pre-clinical studies performed to investigate the therapeutic effectiveness of an eye-drop plasminogen preparation in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. The entity of protection mediated by plasminogen was evaluated by measuring the extent of the eye lesion by means of a computerized system and dedicated software. The results of the present study clearly showed that the administration for six times a day of plasminogen eye-drop solution in the lesioned eye of animals knock-out for plasminogen gene and developing ligneous conjunctivitis caused a dose and time related reduction of the extent of the ocular lesion. These findings may pave the road for the pharmacological treatment of the ocular lesion associated to the ligneous conjunctivitis that at the present is surgically treated by removing the pseudomembranes generated on the eye.",
keywords = "B6.129P2-Plg transgenic mice, Eye lesion, Ligneous conjunctivitis, Plasminogen",
author = "G. Pignataro and A. Vinciguerra and O. Cuomo and R. Sirabella and {Di Renzo}, {G. F.} and A. Scorziello",
year = "2013",
doi = "10.1016/j.phrs.2013.04.012",
language = "English",
volume = "74",
pages = "45--48",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis

AU - Pignataro, G.

AU - Vinciguerra, A.

AU - Cuomo, O.

AU - Sirabella, R.

AU - Di Renzo, G. F.

AU - Scorziello, A.

PY - 2013

Y1 - 2013

N2 - Ligneous conjunctivitis is a severe and rare chronic "idiopathic membraneous" conjunctivitis, characterized by the formation of pseudomembranes mostly on the palpebral surfaces that progressively replace the normal mucosa. Evidence has been provided that ligneous conjunctivitis is caused by a severe systemic plasminogen deficiency with decreased plasminogen antigen and decreased plasminogen functional activities. Objective of the present study is to verify the hypothesis that a topical eye application of plasminogen is able to ameliorate the consequences of this disease. Here we report the results of pre-clinical studies performed to investigate the therapeutic effectiveness of an eye-drop plasminogen preparation in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. The entity of protection mediated by plasminogen was evaluated by measuring the extent of the eye lesion by means of a computerized system and dedicated software. The results of the present study clearly showed that the administration for six times a day of plasminogen eye-drop solution in the lesioned eye of animals knock-out for plasminogen gene and developing ligneous conjunctivitis caused a dose and time related reduction of the extent of the ocular lesion. These findings may pave the road for the pharmacological treatment of the ocular lesion associated to the ligneous conjunctivitis that at the present is surgically treated by removing the pseudomembranes generated on the eye.

AB - Ligneous conjunctivitis is a severe and rare chronic "idiopathic membraneous" conjunctivitis, characterized by the formation of pseudomembranes mostly on the palpebral surfaces that progressively replace the normal mucosa. Evidence has been provided that ligneous conjunctivitis is caused by a severe systemic plasminogen deficiency with decreased plasminogen antigen and decreased plasminogen functional activities. Objective of the present study is to verify the hypothesis that a topical eye application of plasminogen is able to ameliorate the consequences of this disease. Here we report the results of pre-clinical studies performed to investigate the therapeutic effectiveness of an eye-drop plasminogen preparation in B6.129P2-Plgtm1Jld transgenic mice, a model of ligneous conjunctivitis. The entity of protection mediated by plasminogen was evaluated by measuring the extent of the eye lesion by means of a computerized system and dedicated software. The results of the present study clearly showed that the administration for six times a day of plasminogen eye-drop solution in the lesioned eye of animals knock-out for plasminogen gene and developing ligneous conjunctivitis caused a dose and time related reduction of the extent of the ocular lesion. These findings may pave the road for the pharmacological treatment of the ocular lesion associated to the ligneous conjunctivitis that at the present is surgically treated by removing the pseudomembranes generated on the eye.

KW - B6.129P2-Plg transgenic mice

KW - Eye lesion

KW - Ligneous conjunctivitis

KW - Plasminogen

UR - http://www.scopus.com/inward/record.url?scp=84884754065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884754065&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2013.04.012

DO - 10.1016/j.phrs.2013.04.012

M3 - Article

VL - 74

SP - 45

EP - 48

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -